PayerTalkCE Presents: Achieving Appropriate and Equitable Treatment Access for Prostate Cancer Care

Learn About:

The importance of timely identification and appropriate management of prostate cancer
The non-oncologic risks and comorbidities in patients with prostate cancer
Evidence of the disparities in care and access barriers to prostate cancer treatment

Target Audience
This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
Managed care and payer professionals lack knowledge of the disparities in care and barriers to treatment for prostate cancer care, specifically the efficacy and safety profiles of LHRH agonists and GnRH receptor antagonists. These health care professionals need education to improve the quality of treatment across diverse patient populations. In addition, managed care and payer professionals lack knowledge about the non-oncologic risks and comorbidities in patients with prostate cancer.

Educational Objectives
After completing this activity, the participant should be better able to:

Review evidence of the disparities in care and access barriers to prostate cancer treatment with the goal of closing gaps in care and allowing equal access
Explain the evidence supporting the efficacy and safety profiles of Luteinizing hormone-releasing Hormone (LHRH) agonists and Gonadotropin-releasing Hormone (GnRH) receptor antagonists in the treatment of prostate cancer
Assess the importance of timely identification and appropriate management of prostate cancer across diverse patient populations, including aligning treatment selection with patient preferences
Identify the non-oncologic risks and comorbidities in patients with prostate cancer receiving ADT including cardiovascular, metabolic, and bone disease

Accreditation Information

Expert Faculty Presenters:


	Ryan Bitton, PharmD, MBA Senior Director, Pharmacy Services Health Plan of Nevada Click here for biography

	Christopher A. Fausel, PharmD, MHA, BCOP, APRN, FNP-BC Clinical Manager, Oncology Pharmacy Indiana University Simon Cancer Center Click here for biography

	James Kenney, RPh, MBA President JTKENNEY, LLC Click here for biography

	Clayton C. Yates PhD John R. Lewis Professor of Pathology Professor of Pathology, Oncology, Urologic-Oncology Director for Translational Health Disparities and Global Health Equity Research Program Co-Leader for Cancer Genetics and Epigenetics Sidney Kimmel Comprehensive Cancer Center Johns Hopkins School of Medicine Click here for biography

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
PACE designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-23-232-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Name of Faculty*	*Reported Financial Relationship*
Ryan Bitton, PharmD, MBA	Consultant, Advisor, Speaker – Novo Nordisk, AbbVie, Beigene, BridgeBio, Bayer, Hologic, Incyte, Tarsus
James Kenney, RPh, MBA	No financial interest/relationships relating to the topic of this activity.
Christopher A. Fausel, PharmD, MHA, BCOP, APRN, FNP-BC	No financial interest/relationships relating to the topic of this activity.
Clayton Yates, PhD	Consultant, Advisor, Speaker – Prelude DX, Riptide Biosciences, Regeneron, QED Therapeutics Royalties or Patent Beneficiary – Riptide Biosciences

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

*Name of Content Manager*	*Reported Financial Relationship*
PACE Content Managers	No financial relationships to disclose.
Impact Education, LLC Staff	No financial relationships to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.